Intranasal administration of agents with pro-inflammatory activity for the therapy of neurological disorders
The invention concerns a product consisting of distilled water or of an aqueous solution hypotonic or substantially isotonic with respect to blood plasma or, less preferably, hypertonic with respect to blood plasma, to be administered on the nasal mucosa according to a specific operation mode in order to cause an inflammation of an irritative kind, for use in a treatment of stimulation of the endogenous production of inflammatory mediators, in the therapy and prevention of neurological disorders, in particular of degenerative disorders of the central and peripheral nervous system. The inflammatory mediators the endogenous production of which is stimulated comprise NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A.
1. A method for therapy and prophylaxis of at least one pathology selected from the group consisting of pathologies of the central nervous system, pathologies of the peripheral nervous system and neurologic pathologies of the auditory, visual and olfactory apparatus, comprising
selecting a water-based liquid having an osmolality not higher than 130% of a blood plasma osmolality; and
stimulating endogenous production of at least one inflammatory mediator selected from the group consisting of NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, and ECF-A by administering the selected water-based liquid on a nasal-paranasal mucous membrane of the subject;
wherein the administration on the nasal-paranasal mucous membrane is carried out by dispensing an amount of the water-based liquid at a dispensing rate (PEL) ranging from 5.0 g/sec to 15 g/sec, for a dispensing time (ET) ranging from 0.4 sec to 120 sec, with the proviso that a mathematical product of ET and PEL is no greater than 150 g of the dispensed liquid in each administration;
wherein the administration on the nasal-paranasal mucous membrane is carried out at a frequency ranging from 1 to 10 times a day; and
wherein said water-based liquid comprises at least one selected from the group consisting of distilled water, bidistilled water, sterile tap water, physiological solution containing NaCl from 0.9% to 0.01% by weight with optional addition of glucose, Ringer solution, Ringer lactate solution, Hartmann solution, aqueous sulphur solution with a concentration ranging from 0.1 mg to 10 mg of H 2 S per liter, ionized alkaline water with a pH value ranging from 8 to 11, and deionised water.
2. The method according to claim 1 , wherein the administration on the nasal-paranasal mucous membrane is carried out by dispensing an amount of the selected water-based liquid at a dispensing rate (PEL) ranging from 5.0 g/sec to 15 g/sec, for a dispensing time (ET) ranging from 0.4 sec to 10 sec, with the proviso that a mathematical product of ET and PEL is no greater than 150 g of the dispensed water-based liquid in each administration.
3. The method according to claim 2 , wherein the water-based liquid has an osmolality lower than or equal to a blood plasma osmolality.
4. The method according to claim 1 , wherein said water-based liquid is distilled water.
5. The method according to claim 1 , wherein the inflammatory mediator is NGF.
6. The method according to claim 5 , wherein the pathologies are degenerative pathologies of the central nervous system or degenerative pathologies of the peripheral nervous system.
7. The method according to claim 6 , wherein the pathology is at least one selected from the group consisting of Alzheimer's disease, presbiacusis, tinnitus, sudden neurosensorial hypoacusis, and progressive neurosensorial hypoacusis.
8. The method according to claim 1 , wherein the inflammatory mediator is NT-3 or NT.
9. The method according to claim 1 , wherein the inflammatory mediator is serotonin, and the pathologies comprise at least one selected from the group consisting of mood disturbances, restlessness, insomnia, vegetative dystonia, depression, neurasthenia, cephalalgia, eating and appetite disorders, and disorders in sleeping quality.
10. An apparatus for therapy of at least one pathology selected from the group consisting of pathologies of the central nervous system, pathologies of the peripheral nervous system and neurologic pathologies of the auditory, visual and olfactory apparatus by stimulating endogenous production of inflammatory mediators, comprising
a spray dispenser configured to administer a water-based liquid on the nasal-paranasal mucous membrane of a subject,
wherein the spray dispenser has a dispensing rate (PEL) ranging from 5.0 g/sec to 15 g/sec, and is configured to dispense the water-based liquid for a dispensing time (ET) ranging from 0.4 sec to 120 sec, with the proviso that a mathematical product of ET and PEL is no greater than 150 g of the dispensed water-based liquid in each administration;
wherein the water-based liquid has an osmolality not higher than 130% of a blood plasma osmolality; and
wherein the inflammatory mediators are at least one inflammatory mediator selected from the group consisting of NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, and ECF-A.
11. The apparatus according to claim 10 , wherein the apparatus is configured to dispense the water-based liquid comprising at least one selected from the group consisting of distilled water, bidistilled water, sterile tap water, physiological solution containing NaCl from 0.9% to 0.01% by weight with optional addition of glucose, Ringer solution, Ringer lactate solution, Hartmann solution, aqueous sulphur solution with a concentration ranging from 0.1 mg to 10 mg of H 2 S per liter, ionized alkaline water with a pH value ranging from 8 to 11, and deionised water.
12. The apparatus according to claim 10 , wherein the dispensing rate of the spray dispenser is adjustable in the range of 5.0 g/sec to 15 g/sec, and the dispensing time (ET) is adjustable in the range of 0.4 sec to 120 sec.
13. The apparatus according to claim 10 , wherein the apparatus is configured to dispense the water-based liquid to the subject at a frequency of 1 to 10 times a day.